174 related articles for article (PubMed ID: 37600823)
1. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
2. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.
Short NJ; Jabbour E; Jain N; Kantarjian H
J Hematol Oncol; 2024 May; 17(1):32. PubMed ID: 38734670
[TBL] [Abstract][Full Text] [Related]
4. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast.
Jabbour EJ; Stelljes M
Target Oncol; 2024 Mar; 19(2):135-141. PubMed ID: 38457052
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL; Sobecks R; Cho C; Fu P; Margevicius S; Wang J; Ciarrone L; Kopp S; Convents RD; Majhail N; Caimi PF; Otegbeye F; Cooper BW; Gallogly M; Malek E; Tomlinson B; Gerds AT; Hamilton B; Giralt S; Perales MA; de Lima M
Blood Adv; 2024 Mar; 8(6):1384-1391. PubMed ID: 38170741
[TBL] [Abstract][Full Text] [Related]
7. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
8. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
9. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips A; Khoury JD; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris R; Nasr LF; Kriwacki R; Roberts KG; Konopleva MY; Jabbour EJ; Mullighan CG
Blood; 2024 Mar; ():. PubMed ID: 38551807
[TBL] [Abstract][Full Text] [Related]
10. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting.
Russell-Smith A; Murphy L; Nguyen A; Blauer-Peterson C; Terpenning M; Cao F; Li S; Bancroft T; Webb N; Dorman S; Shah R
J Comp Eff Res; 2024 Feb; 13(2):e230142. PubMed ID: 38099517
[No Abstract] [Full Text] [Related]
11. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips AH; Khoury J; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris RS; Nasr LF; Kriwacki RW; Roberts KG; Konopleva M; Jabbour EJ; Mullighan CG
medRxiv; 2023 Dec; ():. PubMed ID: 38106221
[TBL] [Abstract][Full Text] [Related]
12. Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Kopmar NE; Quach K; Gooley TA; Martino CH; Cherian S; Percival MM; Halpern AB; Ghiuzeli CM; Oehler VG; Abkowitz JL; Walter RB; Cassaday RD
JAMA Oncol; 2024 May; ():. PubMed ID: 38722664
[TBL] [Abstract][Full Text] [Related]
13. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults.
Kegyes D; Ghiaur G; Bancos A; Tomuleasa C; Gale RP
Crit Rev Oncol Hematol; 2024 Apr; 196():104317. PubMed ID: 38437908
[TBL] [Abstract][Full Text] [Related]
14. No free rides: management of toxicities of novel immunotherapies in ALL, including financial.
Jain T; Litzow MR
Blood Adv; 2018 Nov; 2(22):3393-3403. PubMed ID: 30482769
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
[TBL] [Abstract][Full Text] [Related]
16. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y; Laird AD; Roberts KG; Yafawi RL; Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour EJ; Cassaday RD; Loyd MR; Olsen SR; Neale GA; Liu X; Vandendries E; Advani AS; Mullighan CG
Blood Adv; 2024 Mar; ():. PubMed ID: 38607410
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.
van Oostrum I; Russell-Smith TA; Jakobsson M; Torup Østby J; Heeg B
Pharmacoecon Open; 2022 Jan; 6(1):47-62. PubMed ID: 34309818
[TBL] [Abstract][Full Text] [Related]
18. Histidine re-sensitizes pediatric acute lymphoblastic leukemia to 6-mercaptopurine through tetrahydrofolate consumption and SIRT5-mediated desuccinylation.
Dong N; Ma HX; Liu XQ; Li D; Liu LH; Shi Q; Ju XL
Cell Death Dis; 2024 Mar; 15(3):216. PubMed ID: 38485947
[TBL] [Abstract][Full Text] [Related]
19. Mutual antagonism between glucocorticoid and canonical Wnt signaling pathways in B-cell acute lymphoblastic leukemia.
Bergeron BP; Barnett KR; Bhattarai KR; Mobley RJ; Hansen BS; Brown A; Kodali K; High AA; Jeha S; Pui CH; Peng J; Pruett-Miller SM; Savic D
Blood Adv; 2023 Aug; 7(15):4107-4111. PubMed ID: 37289547
[No Abstract] [Full Text] [Related]
20. Old rivals become new friends.
Rousselot P
Blood; 2024 Feb; 143(5):380-382. PubMed ID: 38300611
[No Abstract] [Full Text] [Related]
[Next] [New Search]
